Literature DB >> 27314087

Taking out the JNK: A window of opportunity to improve cancer therapy.

Petranel T Ferrao1.   

Abstract

c-JUN-N-terminal kinase (JNK) signaling is a stress-induced response that enables survival of normal cells and is also utilized by cancer cells to evade therapy. Combining JNK inhibitors with standard therapies provides a potential strategy for overcoming drug resistance. Use of the optimal combination dosing and scheduling may substantially improve outcomes for cancer patients.

Entities:  

Keywords:  Combination therapies; EMT; JNK signaling; dosing; drug resistance; early adaptation; phenotype-switching; scheduling; stress response

Year:  2016        PMID： 27314087      PMCID： PMC4909414          DOI： 10.1080/23723556.2015.1128515

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  The c-jun kinase/stress-activated pathway: regulation, function and role in human disease.

Authors:  Gary L Johnson; Kazuhiro Nakamura
Journal:  Biochim Biophys Acta       Date:  2007-01-04

2.  Sustained c-Jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation.

Authors:  Jinhua Wang; Isere Kuiatse; Adrian V Lee; Jingxuan Pan; Armando Giuliano; Xiaojiang Cui
Journal:  Mol Cancer Res       Date:  2010-02-09       Impact factor: 5.852

3.  Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: a role of c-Jun NH2-terminal kinase 1.

Authors:  Fang Li; Li Meng; Jianfeng Zhou; Hui Xing; Shixuan Wang; Gang Xu; Huaishi Zhu; Beibei Wang; Gang Chen; Yun-Ping Lu; Ding Ma
Journal:  Biochem Biophys Res Commun       Date:  2005-10-07       Impact factor: 3.575

4.  The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.

Authors:  Rachel Ramsdale; Robert N Jorissen; Frederic Z Li; Sheren Al-Obaidi; Teresa Ward; Karen E Sheppard; Patricia E Bukczynska; Richard J Young; Samantha E Boyle; Mark Shackleton; Gideon Bollag; Georgina V Long; Eugene Tulchinsky; Helen Rizos; Richard B Pearson; Grant A McArthur; Amardeep S Dhillon; Petranel T Ferrao
Journal:  Sci Signal       Date:  2015-08-18       Impact factor: 8.192

Review 5.  Role of Jun and Jun kinase in resistance of cancer cells to therapy.

Authors:  Irina Vasilevskaya; Peter J O'Dwyer
Journal:  Drug Resist Updat       Date:  2003-06       Impact factor: 18.500

6.  JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells.

Authors:  Shuhei Suzuki; Masashi Okada; Keita Shibuya; Manabu Seino; Atsushi Sato; Hiroyuki Takeda; Shizuka Seino; Takashi Yoshioka; Chifumi Kitanaka
Journal:  Oncotarget       Date:  2015-01-01

7.  The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.

Authors:  Audrey Delmas; Julia Cherier; Magdalena Pohorecka; Claire Medale-Giamarchi; Nicolas Meyer; Anne Casanova; Olivier Sordet; Laurence Lamant; Ariel Savina; Anne Pradines; Gilles Favre
Journal:  Oncotarget       Date:  2015-06-20

8.  Systematic analysis of BRAF(V600E) melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis.

Authors:  Mohammad Fallahi-Sichani; Nathan J Moerke; Mario Niepel; Tinghu Zhang; Nathanael S Gray; Peter K Sorger
Journal:  Mol Syst Biol       Date:  2015-03-26       Impact factor: 11.429

9.  Editorial: Cellular and Phenotypic Plasticity in Cancer.

Authors:  Petranel T Ferrao; Andreas Behren; Robin L Anderson; Erik W Thompson
Journal:  Front Oncol       Date:  2015-08-04       Impact factor: 6.244

10.  JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy.

Authors:  Xinbing Sui; Na Kong; Xian Wang; Yong Fang; Xiaotong Hu; Yinghua Xu; Wei Chen; Kaifeng Wang; Da Li; Wei Jin; Fang Lou; Yu Zheng; Hong Hu; Liu Gong; Xiaoyun Zhou; Hongming Pan; Weidong Han
Journal:  Sci Rep       Date:  2014-04-15       Impact factor: 4.379
  10 in total
  2 in total

Review 1.  The Jun N-terminal kinases signaling pathway plays a "seesaw" role in ovarian carcinoma: a molecular aspect.

Authors:  Yingyu Dou; Xiaoyan Jiang; Hui Xie; Junyu He; Songshu Xiao
Journal:  J Ovarian Res       Date:  2019-10-21       Impact factor: 4.234

2.  Src Cooperates with Oncogenic Ras in Tumourigenesis via the JNK and PI3K Pathways in Drosophila epithelial Tissue.

Authors:  Carole L C Poon; Anthony M Brumby; Helena E Richardson
Journal:  Int J Mol Sci       Date:  2018-05-27       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.